Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT05083364 Recruiting - IgA Nephropathy Clinical Trials

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Start date: February 2, 2022
Phase: Phase 1
Study type: Interventional

The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G] and IgA Nephropathy [IgAN]). In Part 1 of the study, HVs will receive either one or two doses of ARO-C3 or placebo. In Part 2 of the study, adult patients with C3G/IgAN will receive 3 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.

NCT ID: NCT05065970 Completed - Clinical trials for Immunoglobulin A (IgA) Nephropathy

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

IGNAZ
Start date: August 31, 2021
Phase: Phase 2
Study type: Interventional

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

NCT ID: NCT05016323 Recruiting - IgA Nephropathy Clinical Trials

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Start date: September 9, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.

NCT ID: NCT05003986 Recruiting - Clinical trials for Focal Segmental Glomerulosclerosis

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

EPPIK
Start date: August 12, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

NCT ID: NCT04905212 Terminated - IgA Nephropathy Clinical Trials

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Start date: November 4, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.

NCT ID: NCT04887532 Completed - Clinical trials for Primary IgA Nephropathy

A Trial of HR19042 Capsule in Healthy Chinese Subjects

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects. To explore the pharmacokinetic characteristics and safety of HR19042 capsule in healthy Chinese subjects.

NCT ID: NCT04858724 Recruiting - IgA Nephropathy Clinical Trials

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis. 3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation. 4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.

NCT ID: NCT04833374 Recruiting - IgA Nephropathy Clinical Trials

Steroids Therapy in IgA Nephropathy With Crescents

Start date: May 24, 2021
Phase: Phase 3
Study type: Interventional

This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with crescents.

NCT ID: NCT04805047 Recruiting - IgA Nephropathy Clinical Trials

SodiUm Restriction by Behavioral Intervention

SURBI
Start date: May 15, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with immunoglobulin A nephropathy. The test persons in the intervention group are actively supported to adhere to a restricted sodium diet with a structured education program in combination with regular sodium excretion monitoring.

NCT ID: NCT04716231 Recruiting - IgA Nephropathy Clinical Trials

Atacicept in Subjects With IgA Nephropathy

ORIGIN 3
Start date: May 23, 2023
Phase: Phase 3
Study type: Interventional

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)